This titrate-up and taper-down controversy stems from concerns regarding the potential for hyperglycemia upon initiation of total parenteral nutrition (TPN) and for hypoglycemia upon discontinuation.
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback